116 related articles for article (PubMed ID: 17521577)
21. [Hyper-IgE recurrent infection syndrome: pathogenesis, diagnosis and therapeutic management].
Guisado Vasco P; Fraile Rodríguez G; Arechaga Uriarte S
Rev Clin Esp; 2011 Nov; 211(10):520-6. PubMed ID: 21700278
[TBL] [Abstract][Full Text] [Related]
22. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Minegishi Y; Karasuyama H
Int Immunol; 2009 Feb; 21(2):105-12. PubMed ID: 19088064
[TBL] [Abstract][Full Text] [Related]
23. Hyper IgE syndrome: anaphylaxis in a patient carrying the N567D STAT3 mutation.
Merli P; Novara F; Montagna D; Benzo S; Tanzi M; Turin I; De Amici M; Merli A; Zuffardi O; Marseglia GL
Pediatr Allergy Immunol; 2014 Aug; 25(5):503-5. PubMed ID: 24628715
[No Abstract] [Full Text] [Related]
24. Hyper-IgE syndromes: reviewing PGM3 deficiency.
Yang L; Fliegauf M; Grimbacher B
Curr Opin Pediatr; 2014 Dec; 26(6):697-703. PubMed ID: 25365149
[TBL] [Abstract][Full Text] [Related]
25. [Hyper-IgE syndrome with mutation in STAT3 gene - case report and literature review].
Heropolitańska-Pliszka E; Pietrucha B; Mikołuć B; Bernatowska E
Med Wieku Rozwoj; 2009; 13(1):19-25. PubMed ID: 19648655
[TBL] [Abstract][Full Text] [Related]
26. Tyk2 mediates effects of urokinase on human vascular smooth muscle cell growth.
Patecki M; von Schaewen M; Tkachuk S; Jerke U; Dietz R; Dumler I; Kusch A
Biochem Biophys Res Commun; 2007 Aug; 359(3):679-84. PubMed ID: 17548050
[TBL] [Abstract][Full Text] [Related]
27. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Simma O; Zebedin E; Neugebauer N; Schellack C; Pilz A; Chang-Rodriguez S; Lingnau K; Weisz E; Putz EM; Pickl WF; Felzmann T; Müller M; Decker T; Sexl V; Stoiber D
Cancer Res; 2009 Jan; 69(1):203-11. PubMed ID: 19118004
[TBL] [Abstract][Full Text] [Related]
28. A case of exuberant candidal onychomycosis in a child with hyper IgE syndrome.
Cobos G; Rubin AI; Gober LM; Treat JR
J Allergy Clin Immunol Pract; 2014; 2(1):99-100. PubMed ID: 24565777
[No Abstract] [Full Text] [Related]
29. A novel STAT3 mutation in a patient with hyper-immunoglobulin E syndrome.
Ovadia A; Kessel A; Leshinsky-Silver E; Dalal I
Isr Med Assoc J; 2015 Jan; 17(1):62-3. PubMed ID: 25739182
[No Abstract] [Full Text] [Related]
30. Rapid Transition of Facial Features from Early to Mid - Adolescence in Autosomal Dominant Hyper IgE Syndrome with a STAT3 Variation.
Geeta Mg ; Riyaz A; Krishnan C; Scaria V
Indian J Pediatr; 2018 Jul; 85(7):595-596. PubMed ID: 29368105
[No Abstract] [Full Text] [Related]
31. Job syndrome.
Vizán-Caravaca JR; García-Castro JM; López-García S
Med Clin (Barc); 2019 Apr; 152(8):331. PubMed ID: 30220469
[No Abstract] [Full Text] [Related]
32. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
[TBL] [Abstract][Full Text] [Related]
33. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families.
Cunninghame Graham DS; Akil M; Vyse TJ
Rheumatology (Oxford); 2007 Jun; 46(6):927-30. PubMed ID: 17384181
[TBL] [Abstract][Full Text] [Related]
34. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.
Potla R; Koeck T; Wegrzyn J; Cherukuri S; Shimoda K; Baker DP; Wolfman J; Planchon SM; Esposito C; Hoit B; Dulak J; Wolfman A; Stuehr D; Larner AC
Mol Cell Biol; 2006 Nov; 26(22):8562-71. PubMed ID: 16982690
[TBL] [Abstract][Full Text] [Related]
35. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.
Paulson ML; Freeman AF; Holland SM
Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):527-33. PubMed ID: 18978467
[TBL] [Abstract][Full Text] [Related]
36. Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Felgentreff K; Siepe M; Kotthoff S; von Kodolitsch Y; Schachtrup K; Notarangelo LD; Walter JE; Ehl S
Clin Immunol; 2014 Jan; 150(1):43-50. PubMed ID: 24333532
[TBL] [Abstract][Full Text] [Related]
37. TYK2-blocking agent showcases power of atypical kinase.
Dolgin E
Nat Biotechnol; 2022 Dec; 40(12):1701-1704. PubMed ID: 36477502
[No Abstract] [Full Text] [Related]
38. DOCK8 Mutation Syndrome: A Diagnostic Challenge for Dermatologists.
Moreau J; Beaussant-Cohen S; Aubin F; Rohrlich PS; Puzenat E
Acta Derm Venereol; 2016 Nov; 96(7):991-992. PubMed ID: 26573532
[No Abstract] [Full Text] [Related]
39. The hyper-IgE syndrome.
Buckley RH
Clin Rev Allergy Immunol; 2001 Feb; 20(1):139-54. PubMed ID: 11269224
[No Abstract] [Full Text] [Related]
40. Lack of interaction between systemic lupus erythematosus-associated polymorphisms in TYK2 and IRF5.
Suarez-Gestal M; Calaza M; Gonzalez A
J Rheumatol; 2010 Mar; 37(3):676-7; author reply 678. PubMed ID: 20197570
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
